Tirzepatide 30 mg/mL dosage chart
| Dose | Volume to draw | Units (U-100 syringe) |
|---|---|---|
| 2.5 mg | 0.083 mL | 8.3 |
| 5 mg | 0.167 mL | 16.7 |
| 7.5 mg | 0.25 mL | 25 |
| 10 mg | 0.333 mL | 33.3 |
| 12.5 mg | 0.417 mL | 41.7 |
| 15 mg | 0.5 mL | 50 |
Confirm with your pharmacy label and your prescriber before you draw a dose.
How this works
This chart is for tirzepatide vials with a strength of 30 mg per mL. For each dose it divides the milligrams by 30 to get milliliters, then multiplies by 100 to get units on a U-100 insulin syringe.
Example: 5 mg ÷ 30 mg/mL = 0.167 mL, and 0.167 × 100 = 16.7 units.
If your vial shows a different strength, this chart is wrong for it. Pick the chart that matches your label or use the calculator with your exact strength.
Compounded vials are not FDA-approved, and their strength varies from one pharmacy to the next. That is why FDA has reported dosing errors with them. Read dosing errors: mg, mL and units before you measure a dose, and call the pharmacy that supplied the vial if its label and your instructions do not match.
Charts for other vial strengths
Frequently asked questions
How many units is 2.5 mg of tirzepatide at 30 mg/mL?
At 30 mg per mL, 2.5 mg of tirzepatide is 8.3 units on a U-100 insulin syringe. The chart on this page lists every common dose at this strength.
How many units is 5 mg of tirzepatide at 30 mg/mL?
At 30 mg per mL, 5 mg of tirzepatide is 16.7 units on a U-100 insulin syringe. A vial of a different strength gives a different number of units for the same dose.
Is this chart right for every tirzepatide vial?
No. It is only right for vials labeled 30 mg per mL. Check the strength printed on your vial each time you get a new one, and confirm the dose with your pharmacy label and your prescriber.
Sources (2)
- 1.FDA: FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products
“The majority of the reports described patients mistakenly drawing up more than the prescribed dose from a multiple-dose vial during self-administration. In these instances, patients administered five to 20 times more than the intended dose of semaglutide. Most of the reports indicated that patients were unfamiliar with how to measure the intended dose using a syringe.”
- 2.FDA: FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products
“Additionally, the instructions that accompany the compounded drug, if provided, may instruct users to administer semaglutide injections in “units” (the volume of which may vary depending on the concentration), rather than milligrams or milliliters. FDA is aware of some instances in which patients have been given syringes that are significantly larger than the prescribed volume of semaglutide (see example in Figure 1).”
